Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2025
Reporting Period: Fourth quarter and full year ended December 31, 2024
Context: The filing announces the release of financial results for the specified period. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue: Not provided in this document.
- Profit/Loss: Not provided in this document.
- Cash Flow: Not provided in this document.
- Margins: Not provided in this document.
- Debt and Liquidity: Not provided in this document.
Note: Specific values must be obtained from Exhibit 99.1 (Press Release) referenced in the filing.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms that results for the fourth quarter and full year 2024 have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for the full announcement but does not include the text of management commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 13, 2025) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the fourth quarter 2024 performance compared to the fourth quarter 2023.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full press release.
- Confirm the company's cash runway and burn rate as disclosed in the full financial results.